glp-1 or metformin Are GLP-1s and SGLT2s replacements for in addition to Metformin? Clinical Focus on GLP-1 Agonists

Clinical trials have yielded mixed results: several studies, including a phase II trial of NLY01, failed to meet primary endpoints for motor progression, with only modest or nonsignificant effects overall [37,38]

Numerous reports also emphasize the neuroprotective role of GLP-1 mediated signaling, as it was proven to protect synapses, improve synaptic functions, enhance neurogenesis, protect neurons from oxidative stress, and reduce neuronal apoptosis

General advice to patients to reduce salt intake by substituting with nonsalt-containing food flavourings (e.g

Lastly, a Danish population-based register study identified a clear dose-response relationship where increases in T2DM PRS were associated with heightened risk for MDD in both males and females [69]

Microdosing involves starting and staying at much lower dosessometimes as low as 0.1 to 0.25 mg per week for semaglutide or even intermittent use

[20] Over the course of a 52 week double blind study to detect the efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes, the most common side effects seen were nausea, diarrhea, and vomiting [20]